Ocean Pine Healthcare Fund
No. 9, Xiaoyunli South Street, Chaoyang District, Beijing, China
Overview
Oceanpine Healthcare Fund is a healthcare venture fund that aims to connect innovation in the US to the Chinese consumer base, and primarily invests in Chinese and US firms with core technologies and proprietary R&D capabilities. They bridge a supply and demand gap exacerbated by limited R&D in China. Their unique “Dual Market” strategy will help their portfolio companies with local resources and guidance, as well as providing diversification and value-realization for investors.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
- Therapeutics
Investment portfolio
- Refuge Biotechnologies
Participated · Series B · May 2018
Refuge Biotechnologies develops intelligent cell therapeutics engineered to make decisions inside patients using its receptor‑dCas platform, which employs a mutated or dead Cas9 (dCas) to enable precision CRISPR activation and interference. The company is led by co‑founder and CEO Bing C. Wang, Ph.D., with Francesco Marincola, M.D., newly appointed as chief scientific officer. Refuge intends to use the financing to advance cell therapies built on its receptor‑dCas platform and to support collaborative research with partners. As part of the financing, lead investors will have an exclusive right to negotiate development and commercialization rights for therapies using the platform in China. Refuge and 3SBio will collaborate on research to develop programmed cell therapeutics that can produce therapeutic proteins inside a patient’s body. The company is based in Menlo Park, California.
Team
No current team members are available.